Europe should resist US pressure to pay more for medicines and present a united front rather than allowing Washington to negotiate on a country-by-country basis, speakers said during a debate organised by the EU consumer organization BEUC.
The discussion comes as the Trump administration intensifies efforts to reshape pharmaceutical pricing abroad through its “Most Favored Nation” (MFN) policy. After striking a deal with the UK, Washington has turned its attention to Germany, launching a Section 301 investigation into whether the country’s pharmaceutical pricing policies discriminate against US companies….
